Family history of type 2 diabetes and characteristics of children with newly diagnosed type 1 diabetes

Anna Parkkola1,2 · Maaret Turtinen1,2 · Taina Härkönen1,2 · Jorma Ilonen3,4 · Mikael Knip1,2,5,6 · The Finnish Pediatric Diabetes Register

Received: 4 February 2020 / Accepted: 14 October 2020 / Published online: 17 December 2020 © The Author(s) 2020

Abstract

Aims/hypothesis Shared aetiopathogenetic factors have been proposed in type 1 diabetes and type 2 diabetes and both diseases have been shown to cluster in families. Characteristics related to type 2 diabetes have been described in patients with type 1 diabetes with a positive family history of type 2 diabetes. We wanted to characterise the family history of type 2 diabetes and its possible effects on the phenotype and genotype of type 1 diabetes in affected children at diagnosis.

Methods A total of 4993 children under the age of 15 years with newly diagnosed type 1 diabetes from the Finnish Pediatric Diabetes Register were recruited (56.6% boys, median age of 8.2 years) for a cross-sectional, observational, population-based investigation. The family history of diabetes at diagnosis was determined by a structured questionnaire, and markers of metabolic derangement, autoantibodies and HLA class II genetics at diagnosis were analysed.

Results Two per cent of the children had an immediate family member and 36% had grandparents with type 2 diabetes. Fathers and grandfathers were affected by type 2 diabetes more often than mothers and grandmothers. The children with a positive family history for type 2 diabetes were older at the diagnosis of type 1 diabetes ($p < 0.001$), had higher BMI-for-age ($p = 0.01$) and more often tested negative for all diabetes-related autoantibodies ($p = 0.02$).

Conclusions/interpretation Features associated with type 2 diabetes, such as higher body weight, older age at diagnosis and autoantibody negativity, are more frequently already present at the diagnosis of type 1 diabetes in children with a positive family history of type 2 diabetes.

Keywords Autoantibodies · Children · Family history · HLA · Type 1 diabetes · Type 2 diabetes

Introduction

Diabetes mellitus is characterised by hyperglycaemia and inability to control glucose levels. In addition to less frequent subtypes, diabetes has traditionally been classified into two major diseases: type 1 diabetes, which is immune-mediated, and type 2 diabetes, usually related to insulin resistance. This classification is not always straightforward, however, and
shared aetiological and pathogenetic processes have been suggested in both major diabetes types [1, 2]. In addition to classical aggressive autoimmunity and insulin resistance pathways, diabetes could develop from the combination of mild autoimmunity and type 2 diabetes-associated risk factors [2]. Epidemiological findings among adult and paediatric populations support the concept of shared aetiopathogenetic factors; type 1 diabetes and type 2 diabetes have been shown to cluster in families in many studies [3–9], although not in all [10–12]. Family history for type 2 diabetes has been reported in 1–70% of patients with type 1 diabetes, depending on the age of the patients and the time elapsed since type 1 diabetes diagnosis, as well as the extent of family members included in the analysis (e.g. first-degree relatives only vs second- and third-degree relatives also included) [3, 5–7, 10–20]. In paediatric patients with type 1 diabetes, 0–13% have been reported to have first-degree relatives and 32–52% extended family members affected by type 2 diabetes [5, 6, 10, 15, 17, 20].

In previous studies, having family members with type 2 diabetes has increased the risk of developing type 1 diabetes [3–8], and is associated, for example, with later onset of type 1 diabetes, higher rate of the metabolic syndrome, a metabolic profile related to insulin resistance in patients with type 1 diabetes (e.g. higher BMI, larger waist circumference, higher triacylglycerols, decreased insulin sensitivity and higher HbA1c concentrations) and greater risk for diabetic complications [15, 16, 18, 21–23]. On the other hand, a positive family history of type 1 diabetes increases the risk to develop type 2 diabetes [24], and is associated with earlier onset of type 2 diabetes, positivity for GAD antibodies (GADA), a more severe insulin deficiency, higher frequency of the HLA-DQB1*03:02/X genotype, which predisposes to type 1 diabetes, and lower frequencies of hypertension and cardiovascular disease, as well as lower BMI and C-peptide levels [25–27].

Accordingly, type 1 diabetes in the presence of a positive family history for type 2 diabetes seems to have many characteristics traditionally associated with type 2 diabetes. Most of the previous studies are from adult populations with long duration of type 1 diabetes, however. In this study of paediatric patients with newly diagnosed type 1 diabetes from the Finnish Pediatric Diabetes Register, we set out to assess whether such characteristics are already present at the time of diagnosis of type 1 diabetes among children. We compared information on demographic characteristics, metabolic status at diagnosis, type 1 diabetes-related autoantibodies and HLA class II genetics among children with or without a family history for type 2 diabetes.

**Methods**

**Participants** The data are derived from the population-based Finnish Pediatric Diabetes Register and Sample Repository [28]. The Register invites all children and adolescents diagnosed with diabetes in Finland since 2002 and their family members to participate and covers more than 90% of those diagnosed [29]. Approximately 70% of the participants also provide biological samples for the Repository. Children diagnosed with type 1 diabetes between January 2003 and December 2016 under the age of 15 years with samples available for autoantibody analysis and HLA genotyping were included in this study. The sample collection and
characteristics have been described earlier [30]. In brief, 4993 children were included with a male majority (2824/4993, 56.6% boys) and a median age of 8.2 years (ranging from 0.52 to 14.99 years). Children diagnosed under the age of 6 months were excluded, as such infants may have monogenic diabetes. Only one child per family was included as an index case.

Diabetes status and type (type 1, type 2, gestational or other diabetes) of parents, siblings and grandparents were requested using a structured questionnaire [28]. If the family was unsure of the diabetes type, the diabetes doctor or nurse helped with the classification of the disease according to the information provided by the family. For this study, parents or siblings with type 2 diabetes were marked in a questionnaire were considered to have type 2 diabetes if two or more autoantibodies were positive, or if monopositivity for GADA was present in conjunction with HLA genotypes predisposing to type 1 diabetes (risk classification of 3–5 [31]). Those with monopositivity for insulin autoantibodies (IAA) or islet cell antibodies (ICA) were not re-classified. Thus, nine parents were re-classified (six fathers, three mothers) as having type 1 diabetes instead of type 2 diabetes. As serum samples for grandparents and 30 parents were not available, such a re-classification was not possible for these relatives and we relied on the self-reported diabetes type. As we were interested in the situation at the time of type 1 diabetes diagnosis of an index child, only relatives with diabetes diagnosed already at this time point were included. Accordingly, 35 relatives with a known diagnosis of type 2 diabetes at a later time point were classified as not having diabetes. The time of diagnosis for 25 relatives was unknown. The autoantibody-negative children with a family member affected by type 2 diabetes were analysed for the coding and promoter sequences with a next-generation sequencing (NGS) panel including GCK, HNF1a, HNF4a, INS, ABCC8, KCNJ11 and 38 other genes potentially associated with monogenic diabetes (AKT2, APPL1, BLK, CEL, CISD2, DCAF17, DNAJC3, Dyrk1B, Eif2ak3, Foxp3, Gata4, Gata6, Gck, Glis3, Hnf1b, Ier3ip1, Insr, Klf11, Lmna, Neurod1, Neurog3, Pax4, Pcdh1, Pdx1, Pik3r1, Plin1, Pold1, Pparg, Pparg15b, Ptf1a, Rfx6, Scl19a2, Scl2a2, Trmt10a, Wfs1, Zbtb20, Zfp57). None of the children analysed were found to carry any MODY mutation.

The legal guardians of the children and siblings 18 years of age or older gave written, informed consent. Participants aged 10–17 years gave informed assent. The Ethics Committee of the Hospital District of Helsinki and Uusimaa has approved the protocol.

Autoantibodies IAA [32], GADA [33], autoantibodies against islet antigen 2 protein (IA-2A) [34] and zinc transporter 8 autoantibodies (ZnT8A) [35] were analysed with specific radiobinding assays. The cut-off limits were 2.80, 5.36, 0.77 and 0.50 relative units (RU), respectively. These limits were determined as the 99th percentiles in more than 350 Finnish non-diabetic children and adolescents. In the 2003 to 2016 Islet Autoantibody Standardization Program, the disease sensitivities and specificities of the assays were 42–62% and 92–99% for IAA, 64–90% and 90–98% for GADA, 62%–72% and 93–100% for IA-2A, and 48–70% and 97–100% for ZnT8A. ICA levels were analysed with indirect immunofluorescence on human group 0 donor pancreas with a detection limit of 2.5 Juvenile Diabetes Foundation (JDF) units [36]. For calculation of the median antibody titres, only samples at or above the cut-off for antibody positivity were included. We excluded samples taken more than 30 days after the diagnosis of type 1 diabetes from the antibody analyses (n = 255, 5.1%), since after that the IAA assay also detects antibodies to exogenous insulin.

HLA typing We performed HLA typing of major DR-DQ haplotypes as described earlier [37]. HLA class II-conferred risk for type 1 diabetes was estimated by classifying the study participants according to their HLA genotypes into six risk groups ranging from strongly decreased risk (risk group 0) to high risk (risk group 5) [31]. The DRB1*04:01/2/4/5-DQA1*03:01-DQB1*03:02 was denoted as DR4-DQ8, and (DR3)-DQA1*05-DQB1*02 as DR3-DQ2.

Markers of metabolic decompensation at diagnosis At diagnosis of type 1 diabetes, blood pH, HbA1c, plasma glucose and β-hydroxybutyrate levels of the index children were analysed in local laboratories. Standardised HbA1c values were available only from those diagnosed after the year 2012. We defined ketoadidosis as blood pH <7.30 and severe ketoadidosis as blood pH <7.10. Weight loss, level of consciousness and puberty status by the Tanner scale are determined by a clinician at hospital admission.

Data handling and statistical analysis IBM SPSS Statistics 24 (SPSS, IL, USA) and R 3.5.0 package for statistical computing were used for the statistical analyses. For comparing frequencies, cross-tabulation and χ² statistics with continuity correction or Fisher’s exact test when appropriate were used. Differences in levels of variables were analysed with one-way ANOVA or Student’s t test for parametric, and Kruskal–Wallis test or Mann–Whitney U test/Wilcoxon’s rank sum test for non-parametric variables. For variables with more than two groups, linear trend was tested with linear-by-linear test for categorical variables and Jonckheere–Terpsta test for continuous variables. Adjustment for the differences in age and sex was carried out with linear or logistic/ordinal/multinomial regression for parametric or dichotomous/ordinal/categorical variables, and with quantile regression in R (package quantreg 4.54, version 3.5.1) for non-parametric variables [38]. A two-tailed p value of 0.05 or less was considered.
statistically significant. Bonferroni correction for multiple comparisons was not applied due to its overly conservative nature. The \( z \) scores for weight-for-age (only for children up to the age of 10 years), height-for-age and BMI-for-age were calculated with WHO AnthroPlus software [39].

Results

In total, 100 of 4993 (2%) index children at diagnosis of type 1 diabetes had a mother, a father or a sibling diagnosed with type 2 diabetes. Fathers were more commonly affected than mothers: 1.2% (62/4993) vs 0.8% (38/4993) (\( p = 0.02 \)). Only two children had affected siblings. Both of these were from families where a parent was also affected by type 2 diabetes (Fig. 1). Of the 100 children with first-degree family members with type 2 diabetes, 67 also had grandparents affected by type 2 diabetes.

In contrast, a significant proportion of the children had a grandparent affected by type 2 diabetes: 1787 of 4993 index children (36%) reported at least one affected grandparent. In total, 2140 of the 19,972 grandparents (10.7%) had type 2 diabetes. Again, grandfathers were more commonly affected than grandmothers: 1108 (22.2%) of the index children reported at least one grandfather with type 2 diabetes compared with 896 (17.9%) reporting an affected grandmother (\( p < 0.001 \)). Of the grandfathers, 11.9% (1191/9986), and of the grandmothers, 9.5% (949/9986), reported type 2 diabetes (\( p < 0.001 \)). Grandparents from the maternal side were affected equally often as grandparents from the paternal side of the family (20.7 vs 19.5%, \( p = 0.13 \)).

We compared the children with immediate family members affected by type 2 diabetes (\( n = 100 \)), the children with only grandparents affected by type 2 diabetes (\( n = 1720 \)) and the children with no first-degree relatives or grandparents known to have type 2 diabetes (\( n = 3173 \)) at the time of diagnosis of type 1 diabetes in the index child. The children with a family history of type 2 diabetes were significantly older at diagnosis (Table 1). There was a significant decreasing trend in age at diagnosis: the children with type 2 diabetes in the immediate family members were the oldest, the children with affected grandparents were of intermediate age and the children without a family history of type 2 diabetes were the youngest (\( p \) for trend <0.001). Accordingly, a similar trend existed for being pubertal, as the older children had more often reached puberty (Tanner stage 2 or higher) (\( p \) for trend <0.001). Consequently, all the analyses were then adjusted for the differences in age at diagnosis and sex. Adjustment removed the significance in being pubertal. After adjustment, the children with a positive family history of type 2 diabetes had higher BMI-for-age \( z \) scores, with the children with affected first-degree relatives being the heaviest and those without family history for type 2 diabetes the lightest (\( p \) for trend <0.001). After adjustment, there were no differences in the markers of metabolic decompensation at diagnosis, e.g. plasma glucose levels, \( \text{HbA}_{1c} \), weight loss, frequency of ketoacidosis (Table 2). When comparing autoantibodies, however, the children with first-degree family members with type 2 diabetes were more often negative for all five autoantibodies (Table 3). ICA levels were higher among children with affected grandparents compared with children without a type 2 diabetes family history. There were no significant differences in the frequencies of HLA class II haplotypes or genotypes (electronic supplementary material [ESM] Table 1). However, there was a tendency for more children with a protective HLA genotype and fewer with a high-risk HLA genotype in those with first-degree relatives affected by type 2 diabetes compared with those with affected grandparents or no affected relatives (3.0% vs 0.8% and 0.7% for the protective risk group 0, and 14.0% vs 22.0% and 21.3% for the high-risk group 5).

When the children with affected first-degree relatives or grandparents were pooled together, those with a positive family history for type 2 diabetes (\( n = 1820 \)) were older, and after age and sex adjustment had higher BMI-for-age \( z \) scores and higher levels of ICA compared with children without a type 2 diabetes family history (ESM Table 2). There were no differences in HLA genetics.

Discussion

In our cohort of children newly diagnosed with type 1 diabetes, only 2% of the children reported type 2 diabetes patients among their immediate family members, whereas type 2 diabetes in grandparents was common (36% of the children reported affected grandparents). These figures are in line with those previously reported for children newly diagnosed with type 1 diabetes: in Sweden, 1.7% reported affected immediate family members and 31% reported affected grandparents [5], and in Serbia the figures were 13% and 34%, respectively [6]. In our study, type 2 diabetes seemed more prevalent among fathers and grandfathers compared with mothers and grandmothers. Previous reports from the time of type 1 diabetes diagnosis agree with this result [3, 6, 20], whereas surveys on children [10] and adults [40] with longer duration of type 1 diabetes report equal male–female distribution or even higher maternal prevalence of type 2 diabetes [16]. Our result concurs with epidemiological findings of type 2 diabetes being in general more common among men, and of men being diagnosed with type 2 diabetes at a younger age than women [41]. For reports with maternal overrepresentation, recollection and ascertainment biases in the form of mothers possibly being more aware of the diseases of their relatives and being the parent responsible for answering the study questions might play a role.
We noted an older age at diagnosis of type 1 diabetes among children with a family history for type 2 diabetes. A possible source of bias in this cross-sectional setting is that older patients have in general older family members who are, by definition, more likely to have developed type 2 diabetes. However, our results are in accordance with many previous findings in adults and children [5, 15, 19, 42]. Although, in a previous study from Finland, older age at onset of type 1 diabetes was observed only in adults with a positive family history of type 2 diabetes, and not among those under the age of 15 years [16].

In age- and sex-adjusted analyses, the children with a family history for type 2 diabetes were heavier according to the dotted lines indicate those occasions where there are two affected family members, but both family members have already been included in the total number in that category.

Fig. 1 Flowchart displaying the numbers and the proportions of participants with relatives affected by type 2 diabetes in different groups in the total cohort of 4993 children with newly diagnosed type 1 diabetes. The
### Table 1  
Comparison of demographic and anthropometric characteristics among children with first-degree relatives (I), grandparents (II), or no-one in the family (III) affected by type 2 diabetes

| Characteristic                         | n     | I. T2D in first-degree relatives (n = 100) | II. T2D in grandparents (n = 1720) | III. No T2D in family (n = 3173) | Unadjusted p value<sup>a</sup> | Age- and sex-adjusted p value<sup>a</sup> | p for trend |
|----------------------------------------|-------|--------------------------------------------|-----------------------------------|---------------------------------|--------------------------------|---------------------------------|------------|
| Age at diagnosis, years, median (range)| 4993  | 10.6 (1.5–14.7)                             | 8.6 (0.5–14.99)                   | 7.8 (0.5–14.99)                 | <0.001                        | <0.001                         | <0.001     |
| Sex, male, % (95% CI)                  | 4993  | 61.0 (51.4, 70.6)                           | 58.1 (55.7, 60.4)                 | 55.6 (53.9, 57.3)               | 0.16                          | 0.16                           |            |
| Familial T1D (1st degree), % (95% CI)  | 4993  | 7.0 (2.0, 12.0)                             | 10.1 (8.7, 11.5)                  | 10.7 (9.6, 11.7)                | 0.45                          | 0.45                           |            |
| Pubertal, % (95% CI)                   | 3764  | 34.9 (23.1, 46.7)                           | 19.5 (17.4, 21.7)                 | 15.4 (13.9, 16.8)               | <0.001                        | 0.98                           | <0.001     |
| Weight-for-age z score, median (range) | 3162  | 0.44 (−1.7 to 6.4)                          | 0.24 (−3.1 to 5.2)                | 0.17 (−3.5 to 6.1)              | 0.11                          | 0.23                           |            |
| Height/length-for-age z score, median (range) | 4828 | 0.64 (−2.1 to 3.5)                           | 0.49 (−2.7 to 4.5)                | 0.51 (−3.4 to 6.2)              | 0.78                          | 0.25                           |            |
| BMI-for-age z score, median (range)    | 4820  | 0.28 (−3.4 to 5.5)                          | −0.21 (−4.9 to 6.0)               | −0.27 (−4.6 to 6.0)             | 0.003                         | 0.007                          |            |

<sup>a</sup> The first p values refer to comparisons across all groups, whereas the ones below refer to each separate two-way comparison

T1D, type 1 diabetes; T2D, type 2 diabetes
BMI-for-age z score. This is in accordance with previous reports in children and adults [15, 16], although not all studies agree [19, 22]. The finding is easily explained, as obesity is an important risk factor for type 2 diabetes, and obesity clusters

Table 3  Comparison of type 1 diabetes-related autoantibodies among children with first-degree relatives (I), grandparents (II), or no-one in the family (III) affected by type 2 diabetes

| Variable                          | n  | I. T2D in first-degree relatives (n = 100) | II. T2D in grandparents (n = 1720) | III. T2D in family (n = 3173) | Unadjusted p value | Age- and sex-adjusted p value |
|-----------------------------------|----|------------------------------------------|-----------------------------------|-------------------------------|-------------------|-----------------------------|
| ICA, % (95% CI)                   | 4738 | 85.1 (77.9, 92.3)                       | 91.9 (90.6, 93.3)               | 91.9 (90.9, 92.8)             | 0.06              | 0.16                        |
| ICA, JDFU, median (range)         | 4347 | 56.5 (3–4906)                           | 64.0 (3–4906)                   | 49.0 (3–5120)                 | 0.02              | 0.002                       |
| IAA, % (95% CI)                   | 4738 | 26.6 (17.7, 35.5)                       | 42.7 (40.3, 45.1)              | 43.7 (41.9, 45.5)             | 0.004             | 0.16                        |
| IAA, RU, median (range)           | 2037 | 10.5 (3.2–317.0)                        | 10.1 (2.9–7809)                | 10.3 (2.8–484.9)             | 0.63              | 0.91                        |
| IA-2A, % (95% CI)                 | 4738 | 68.1 (58.7, 77.5)                       | 75.6 (73.5, 77.6)              | 75.0 (73.5, 76.5)             | 0.27              | 0.22                        |
| IA-2A, RU, median (range)         | 3556 | 96.0 (1.0–225.6)                        | 105.4 (0.8–501.0)              | 105.9 (0.8–553.3)            | 0.53              | 0.76                        |
| GADA, % (95% CI)                  | 4738 | 64.9 (55.2, 74.5)                       | 68.3 (66.0, 70.5)              | 65.4 (63.7, 67.1)             | 0.13              | 0.12                        |
| GADA, RU, median (range)          | 3144 | 34.3 (5.8–319.5)                        | 35.7 (5.4–15,839)             | 36.1 (5.4–24,849.0)           | 0.87              | 0.93                        |
| ZnT8A, % (95% CI)                 | 4738 | 73.4 (64.5, 82.3)                       | 71.3 (69.1, 73.5)              | 68.3 (66.6, 69.9)             | 0.08              | 0.20                        |
| ZnT8A, RU, median (range)         | 3289 | 10.5 (0.6–170.7)                        | 12.8 (0.5–209.3)               | 11.8 (0.5–1201.9)            | 0.88              | 0.80                        |
| Positive antibody responses, median (mean) | 4738 | 3 (3.2)                                  | 4 (3.5)                         | 4 (3.4)                      | 0.10              | 0.35                        |
| Antibody multipositive, % (95% CI)| 4738 | 85.1 (77.9, 92.3)                       | 93.0 (91.8, 94.3)              | 92.4 (91.5, 93.4)             | 0.02              | 0.05                        |
| Antibody negative, % (95% CI)     | 4738 | 7.4 (2.1, 12.8)                         | 2.0 (1.3, 2.7)                 | 2.3 (1.7, 2.8)               | 0.01              | 0.02                        |

T2D, type 2 diabetes

BMI-for-age z score. This is in accordance with previous reports in children and adults [15, 16], although not all studies agree [19, 22]. The finding is easily explained, as obesity is an important risk factor for type 2 diabetes, and obesity clusters

Table 2  Comparison of measures of metabolic decompensation at diagnosis of type 1 diabetes among children with first-degree relatives (I), grandparents (II), or no-one in the family (III) affected by type 2 diabetes

| Variable                          | n  | I. T2D in first-degree relatives (n = 100) | II. T2D in grandparents (n = 1720) | III. T2D in family (n = 3173) | Unadjusted p value | Age- and sex-adjusted p value |
|-----------------------------------|----|------------------------------------------|-----------------------------------|-------------------------------|-------------------|-----------------------------|
| Plasma glucose, mmol/l, median (range) | 4869 | 22.2 (5.3–71.0)                       | 23.8 (3.5–97.6)                 | 24.0 (3.2–94.6)             | 0.16              | 0.62                        |
| Ketoacidosis, % (95% CI)          | 4817 | 20.6 (12.6, 28.7)                       | 18.6 (16.7, 20.4)               | 17.5 (16.2, 18.9)            | 0.54              | 0.90                        |
| Severe ketoacidosis, % (95% CI)   | 4817 | 5.2 (0.8, 9.6)                          | 4.4 (3.4, 5.4)                  | 4.7 (4.0, 5.5)               | 0.81              | 0.74                        |
| pH, median (range)                | 4817 | 7.38 (6.82–7.53)                        | 7.38 (6.72–7.57)                | 7.38 (6.79–7.54)             | 0.45              | 0.90                        |
| ß-hydroxybutyrate, mmol/l, median (range) | 4384 | 1.7 (0.06–16.7)                        | 1.8 (0–23.5)                    | 1.7 (0–27.0)                 | 0.95              | 0.76                        |
| Impaired consciousness, % (95% CI)| 4784 | 6.1 (1.4, 10.8)                         | 5.6 (4.5, 6.7)                  | 5.3 (4.5, 6.1)               | 0.91              | 0.94                        |
| HbA1c, mmol/mol, mean (SD)        | 841  | 101.9 (33.1)                           | 93.8 (28.1)                     | 93.2 (27.3)                  | 0.27              | 0.67                        |
| Weight loss, %, median (range)    | 4610 | 5.2 (0–24)                              | 5.5 (0–35)                      | 5.1 (0–40)                   | 0.26              | 0.25                        |
| Duration of symptoms, %           | 4614 |                                          | 0.03                            | 0.18                         |                   |                             |
| No symptoms                       | 0   | 1.1                                      | 0.9                             |                               |                   |                             |
| <1 week                           | 22.7| 22.7                                     | 22.7                            |                               |                   |                             |
| 1–4 weeks                         | 47.4 | 55.9                                     | 58.7                            |                               |                   |                             |
| >4 weeks                          | 29.9 | 20.4                                     | 17.9                            |                               |                   |                             |

*The first p values refer to comparisons across all groups, while the ones below refer to each separate two-way comparison

'Multipositive’ means positive for at least two of the measured autoantibodies

JDFU, Juvenile Diabetes Foundation units; T1D, type 1 diabetes; T2D, type 2 diabetes
in families due to genetic and lifestyle-based reasons. Accordingly, it seems that the family history of type 2 diabetes translates to higher BMI already at the diagnosis of childhood type 1 diabetes.

A novel finding is that children with newly diagnosed type 1 diabetes were more likely to test negative for diabetes-related autoantibodies at diagnosis if they had family members with type 2 diabetes. In the Diabetes Control and Complications Trial study among adults with longstanding type 1 diabetes, no association was found with autoantibodies and family history of type 2 diabetes [23]. However, only GADA and IA-2A were analysed in that study. Higher frequency of autoantibody-negative patients resonates well with the previous findings of type 2 diabetes-related characteristics among type 1 diabetes patients with a positive family history for type 2 diabetes. Among patients with longer duration of type 1 diabetes, markers related to the metabolic syndrome and insulin resistance have been associated with a positive family history for type 2 diabetes [15, 16, 18, 21–23]. Additionally, patients with newly diagnosed type 1 diabetes have been observed to enter clinical remission more often if they have relatives with type 2 diabetes compared with those without type 2 diabetes in the family [43]. Such patients might have factors related to insulin resistance contributing to the development of diabetes and leading to lower need for aggressive autoimmunity for the disease development. This hypothesis is supported by the distinct features discovered among patients who have developed type 1 diabetes despite having no or only one autoantibody. Such patients often carry the type 2 diabetes-associated TCF7L2 gene variant [44] and are more often overweight compared with patients with a more severe autoimmune reaction, i.e. multiple autoantibodies [45]. In summary, the results reported by us and by others offer accumulating evidence that in a subset of children with type 1 diabetes, pathogenetic factors related to type 2 diabetes might be involved in the disease development. This may suggest milder autoimmunity in the pathogenesis of type 1 diabetes in these patients with characteristics of both type 1 and 2 diabetes. In such patients, the glycaemic control homeostasis could already be compromised at baseline due to genetic and lifestyle-related factors, and even a mild autoimmune reaction could lead to insufficient insulin action and development of clinical diabetes. Importantly, despite suggesting less aggressive autoimmunity, we detected no indication for a milder metabolic disturbance (e.g. lower plasma glucose levels or less ketoacidosis) at the diagnosis of type 1 diabetes among those with a family history for type 2 diabetes. This would mean that despite the milder autoimmune reaction, this subset of children are not protected from the life-threatening glycaemic crisis at diagnosis and require as rapid medical intervention as the children with a classical severe autoimmune reaction. Larger studies are needed to confirm whether this is the case.

In accordance with previous studies [16, 19], we detected no significant differences in HLA genetics between children with and children without a family history for type 2 diabetes. A tendency existed, however, for more children with protective HLA genetics in the group with first-degree relatives affected by type 2 diabetes. It is likely that this group could have genetic factors associated with type 2 diabetes, but unfortunately these were not analysed in our cohort.

Our study is a cross-sectional, observational investigation of a large, population-based sample of children with newly diagnosed type 1 diabetes. We wanted to investigate the effects of a positive family history for type 2 diabetes on metabolic characteristics, autoantibodies and HLA genetics in children with newly diagnosed type 1 diabetes, as information among paediatric patients at diagnosis is lacking. To our knowledge, the current survey is the first study to compare markers of metabolic derangement and autoantibodies at diagnosis of type 1 diabetes according to family history of type 2 diabetes. Our study is based on a large, population-based register and we have samples available for autoantibody and HLA analyses from a large sample. Consequently, our data are limited to the time of diagnosis of type 1 diabetes of the index children, and we do not have follow-up data available to determine possible later development of type 2 diabetes in family members. Studies with follow-up data might result in a higher number of children with a positive type 2 diabetes family history and thus stronger power for the comparisons. Additionally, our study does not include a control group and thus we are unable to compare the prevalence of type 2 diabetes among family members of type 1 diabetes patients and of control participants. As we do not have measurements such as BMI or weight to help in the classification of diabetes in the relatives, we rely mostly on self-reports of the families. Furthermore, family members of a patient with one type of diabetes are de facto at increased risk for the same type of diabetes, which complicates classification in clinical and research settings. To be better able to analyse the possible pathogenetic factors behind the different subsets of patients, factors related to the metabolic syndrome, for example, lipid levels or measures of insulin resistance from the index children, would have been interesting. Unfortunately, such measurements were not possible in such a large cohort.

If a child with diabetes tests negative for disease-associated autoantibodies at diagnosis, one has to consider alternative diagnoses, such as type 2 diabetes or monogenic diabetes. In follow-up studies of risk individuals we have seen that sometimes a child that tests autoantibody-positive preclinically is autoantibody-negative at diagnosis. We can not totally exclude the possibility that some of the autoantibody-negative children in our study cohort had in fact type 2 diabetes or some other diabetes type instead of type 1 diabetes. We believe this number to be small, however, as type 2 diabetes in children in Finland is still rare, and careful diagnostic procedures are performed in paediatric units in Finland. Additionally, to exclude any cases of monogenic diabetes,
children diagnosed with type 1 diabetes at a very young age were excluded and autoantibody-negative children with a first-degree relative affected by type 2 diabetes underwent NGS analysis of 44 genes potentially associated with monogenic diabetes, including seven MODY genes (GCK, HNF1A, HNF1B, HNF4A, INS, ABCC8, KCNJ11). There could also be the rare possibility that a child might have autoantibodies to a so far uncharacterised antigen.

In conclusion, our findings emphasise the heterogeneity of diabetes and imply possible shared aetiopathogenetic factors with type 2 diabetes in some children with type 1 diabetes. Further studies are needed to better understand this heterogeneity in the pathogenetic processes. Nevertheless, children with a positive family history for type 2 diabetes could benefit from recognition of type 2-related risk factors in the prediction, prevention and management of their diabetes.

Supplementary Information The online version contains peer-reviewed but unedited supplementary material available at https://doi.org/10.1007/s00125-020-05342-x.

Acknowledgements We thank all the participants, hospitals and personnel of the Finnish Pediatric Diabetes Register.

Data availability Data are available on reasonable request from the corresponding author.

Funding Open access funding provided by University of Helsinki including Helsinki University Central Hospital. The study was supported by the Academy of Finland (Decision No. 292538, and Centre of Excellence in Molecular Systems Immunology and Physiology Research 2012–2017, Decision No. 250114), the Sigrid Jusélius Foundation, Finska Läkaresällskapet, and the Liv and Hälsa Fund.

Authors’ relationships and activities The authors declare that there are no relationships or activities that might bias, or be perceived to bias, their work.

Contribution statement AP analysed the data, wrote the first version of the manuscript, edited the manuscript and approved the final manuscript as submitted. MT compiled the data for the analyses, reviewed the manuscript, contributed to the discussion and approved the final manuscript as submitted. TH was in charge of the autoantibody laboratory, reviewed the manuscript, contributed to the discussion and approved the final manuscript as submitted. TM compiled the data for the analyses, reviewed the manuscript and approved the final manuscript as submitted. MK planned the study, contributed to the discussion, reviewed the manuscript and approved the final manuscript as submitted. MK is the guarantor of this work and, as such, had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. The participants of the Finnish Pediatric Diabetes Register were involved in the planning of the study design and collection of data.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

References

1. Wilkin TJ (2001) The accelerator hypothesis: weight gain as the missing link between type I and type II diabetes. Diabetologia 44(7):914–922. https://doi.org/10.1007/s001250100548

2. Redondo MJ, Evans-Molina C, Steck AK, Atkinson MA, Sosenko J (2019) The influence of type 2 diabetes–associated factors on type 1 diabetes. Diabetes Care 42(8):1357. https://doi.org/10.2337/dc19-0102

3. Allen C, Palta M, D’Alessio DJ (1991) Risk of diabetes in siblings and other relatives of IDDM subjects. Diabetes 40(7):831–836. https://doi.org/10.2337/dbiab.40.7.831

4. Chem MM, Anderson VE, Barbosa J (1982) Empirical risk for insulin-dependent diabetes (IDD) in sibs: further definition of genetic heterogeneity. Diabetes 31(12):1115–1118. https://doi.org/10.2337/diarec.31.12.1115

5. Dahlquist G, Blom L, Tuuveno T, Nyström L, Sandström A, Wall S (1989) The Swedish childhood diabetes study – results from a nine year case register and a one year case-referent study indicating that type 1 (insulin-dependent) diabetes mellitus is associated with both type 2 (non-insulin-dependent) diabetes mellitus and autoimmune disorders. Diabetologia 32(1):2–6. https://doi.org/10.1007/BF00265396

6. Sipetic S, Vlajinac H, Kocic N, Marinkovic J, Radmanovic S, Denic L (2002) Family history and risk of type 1 diabetes mellitus. Acta Diabetol 39(3):111–115. https://doi.org/10.1007/s0059200200028

7. Wagener DK, Sacks JM, LaPorte RE, Maegregor JM (1982) The Pittsburgh study of insulin-dependent diabetes mellitus. Risk for diabetes among relatives of IDDM. Diabetes 31(2):136–144. https://doi.org/10.2337/diab.31.2.136

8. Weires MB, Tausch B, Haug PJ, Edwards CQ, Wetter T, Cannon-Albright LA (2007) Familiality of diabetes mellitus. Exp Clin Endocrinol Diabetes 115(10):634–640. https://doi.org/10.1055/s-2007-984443

9. Weiss PA, Scholz HS, Haas J, Tamussino KF, Seissler J, Borkenstein MH (2000) Long-term follow-up of infants of mothers with type 1 diabetes: evidence for hereditary and nonhereditary transmission of diabetes and precursors. Diabetes Care 23(7):905–911. https://doi.org/10.2337/diabetes.23.7.905

10. Alhonen S, Korhonen S, Tapapaninen P, Knip M, Veijola R (2011) Extended family history of diabetes and autoimmune diseases in children with and without type 1 diabetes. Diabetes Care 34(1):115–117. https://doi.org/10.2337/dc10-1091

11. Alothbeli E, Chiarelli F, Valenti M, Verrotti A, Blasetti A, Oriu FD (1998) Family history and risk of insulin-dependent diabetes mellitus: a population-based case-control study. Acta Diabetol 35(1):57–60. https://doi.org/10.1007/s005920050102

12. Douek IF, Gillespie KM, Bingley PJ, Gale EA (2002) Diabetes in the parents of children with type I diabetes. Diabetologia 45(4):495–501. https://doi.org/10.1007/s00125-002-0790-0

13. Barone B, Rodacci M, Zajdenberg L et al (2008) Family history of type 2 diabetes is increased in patients with type 1 diabetes. Diabetes Res Clin Pract 82(1):e1–e4. https://doi.org/10.1016/j.diabres.2008.03.015

14. Douek IF, Gillespie KM, Dix RJ, Bingley PJ, Gale EA (2003) Three generations of autoimmune diabetes: an extended family
study. Diabetologia 46(10):1313–1318. https://doi.org/10.1007/s00125-003-1186-5

15. Gilliam LK, Liese AD, Bloch CA et al (2007) Family history of diabetes, autoimmunity, and risk factors for cardiovascular disease among children with diabetes in the SEARCH for Diabetes in Youth Study. Pediatr Diabetes 8(6):354–361. https://doi.org/10.1111/j.1399-5448.2007.00241.x

16. Thom LM, Forsblom C, Waden J et al (2009) Effect of parental type 2 diabetes on offspring with type 1 diabetes. Diabetes Care 32(1):63–68. https://doi.org/10.2337/dc08-0472

17. Hathout EH, Thomas W, El-Shahawy M, Nahab F, Mace JW (2001) Diabetic autoimmune markers in children and adolescents with type 2 diabetes. Pediatrics 107(6):e102. https://doi.org/10.1542/peds.107.6.e102

18. Tsepe B, Bergis K (1991) Epidemiological evidence for “double diabetes.” Lancet 337(8737):361–362. https://doi.org/10.1016/0140-6736(91)90988-2

19. Zalloua PA, Shbaklo H, Halaby G, Terwedow H, Xu X, Azar ST (2019) Autoantibodies in diabetes mellitus: a sensitive marker of IDDM with clinical onset in childhood and adolescence. Childhood Diabetes in Finland Study Group. Diabetologia 41(4):424–429. https://doi.org/10.1007/s001250050925

20. Malachowska B, Baranowska-Jazwiecka A, Hogendorf A, Szadkowska A, Fendler W, Mlynarski W (2012) Unequal contribution of familial factors to autoimmunity and clinical course of childhood diabetes. Pediatr Endocrinol Diabetes Metab 18(4):130–136

21. Fagerudd JA, Pettersson-Fernholm KJ, Grönhagen-Riska C, Groop P-H (1999) The impact of a family history of type II (non-insulin-dependent) diabetes mellitus on the risk of diabetic nephropathy in patients with concurrent type 1 (insulin-dependent) diabetes mellitus. Diabetologia 42(5):519–526. https://doi.org/10.1007/s001250051189

22. Erbey JR, Kuller LH, Becker DJ, Orchard TJ (1998) The association between a family history of type 2 diabetes and coronary artery disease in a type 1 diabetes population. Diabetes Care 21(4):610–614. https://doi.org/10.2337/diabetes.42.5.519

23. Purnell JQ, Dev RK, Steffes MW et al (2003) Relationship of family history of type 2 diabetes, hypoglycemia, and autoantibodies to weight gain and lipids with intensive and conventional therapy in the Diabetes Control and Complications Trial. Diabetes 52(10):2623–2629. https://doi.org/10.2337/diabetes.52.10.2623

24. Lundgren VM, Isomaa B, Lyssenko V et al (2010) GAD antibody positivity predicts type 2 diabetes in an adult population. Diabetes 59(2):416–422. https://doi.org/10.2337/db09-0747

25. Li H, Isomaa B, Taskinen MR, Groop L, Tuomi T (2000) Consequences of a family history of type 1 and type 2 diabetes on the phenotype of patients with type 2 diabetes. Diabetes Care 23(5):589–594. https://doi.org/10.2337/diacare.23.5.589

26. Li H, Lindholm E, Almgren P et al (2001) Possible human leukocyte antigen-mediated genetic interaction between type 1 and type 2 diabetes. J Clin Endocrinol Metab 86(2):574–582. https://doi.org/10.1210/jcem.86.2.7170

27. Lundgren VM, Andersen MK, Isomaa B, Tuomi T (2012) Family history of type 1 diabetes affects insulin secretion in patients with ‘type 2’ diabetes. Diabet Med 30(5):e163–e169. https://doi.org/10.1111/dme.12069

28. Parkkola A, Härkönen T, Ryyhänen SJ, Ilonen J, Knip M, Finnish Pediatric Diabetes Register (2013) Extended family history of type 1 diabetes and phenotype and genotype of newly diagnosed children. Diabetes Care 36(2):348–354. https://doi.org/10.2337/dc12-0445

29. Hekkala A, Reunanen A, Koski M, Knip M, Veijola R, Finnish Pediatric Diabetes Register (2010) Age-related differences in the frequency of ketoadiabetic response at diagnosis of type 1 diabetes in children and adolescents. Diabetes Care 33(7):1500–1502. https://doi.org/10.2337/dc09-2344

30. Turtinen M, Härkönen T, Parkkola A, Ilonen J, Knip M (2018) Sex as a determinant of type 1 diabetes at diagnosis. Pediatr Diabetes 19(7):1221–1228. https://doi.org/10.1111/pedi.12697

31. Ilonen J, Kivineni M, Lempainen J et al (2016) Genetic susceptibility to type 1 diabetes in childhood — estimation of HLA class II associated disease risk and class II effect in various phases of islet autoimmunity. Pediatr Diabetes 17(Suppl 22):8–16. https://doi.org/10.1111/pedi.12327

32. Ronkainen MS, Hämäläinen AM, Koskela P, Åkerblom HK, Knip M, Finnish TRIGR Study Group (2001) Pregnancy induces nonimmunoglobulin insulin-binding activity in both maternal and cord blood serum. Clin Exp Immunol 124(2):190–196. https://doi.org/10.1046/j.1365-2249.2001.01506.x

33. Savola K, Sabbah E, Kulmala P, Vähäsalo P, Ilonen J, Knip M (1998) Autoantibodies associated with type 1 diabetes mellitus persist after diagnosis in children. Diabetologia 41(11):1293–1297. https://doi.org/10.1007/s001250051016

34. Savola K, Bonifacio E, Sabbah E et al (1998) IA-2 antibodies — a sensitive marker of IDDM with clinical onset in childhood and adolescence. Childhood Diabetes in Finland Study Group. Diabetologia 41(4):424–429. https://doi.org/10.1007/s001250050925

35. Salonen KM, Ryhänen S, Härkönen T, Ilonen J, Knip M, Finnish Pediatric Diabetes Register (2013) Autoantibodies against zinc transporter 8 are related to age, metabolic state and HLA DR genotype in children with newly diagnosed type 1 diabetes. Diabetes Metab Res Rev 29(8):646–654. https://doi.org/10.1002/dmr.2440

36. Bottazzo GF, Florin-Christensen A, Doniach D (1974) Islet-cell antibodies in diabetes mellitus with autoimmune polyendocrine deficiencies. Lancet 2(7892):1279–1283. https://doi.org/10.1016/s0140-6736(74)90140-8

37. Hermann R, Turpeinen H, Laine AP et al (2003) HLA DR-DQ-encoded genetic determinants of childhood-onset type 1 diabetes in Finland: an analysis of 622 nuclear families. Tissue Antigens 62(2):162–169. https://doi.org/10.1034/j.1399-0039.2003.00071.x

38. R Core Team (2013) R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. https://doi.org/10.18637/jss.v062.i03

39. WHO (2009) WHO AnthroPlus for personal computers manual: software for assessing growth of the world’s children and adolescents. Available from https://www.who.int/growthref/tools. Accessed 15 Oct 2018

40. Hadjadj S, Duengler F, Torremocha F et al (2007) Maternal history of type 2 diabetes is associated with diabetic nephropathy in type 1 diabetic patients. Diabetes Metab 33(1):37–43. https://doi.org/10.1016/j.diabet.2006.09.003

41. Kautzky-Willer A, Harreiter J, Pacini G (2016) Sex and gender differences in risk, pathophysiology and complications of type 2 diabetes mellitus. Endocr Rev 37(3):278–316. https://doi.org/10.1210/er.2015-1137

42. Holstein A, Patzer O, Tiemann T, Vortherms J, Kovacs P (2012) Number and sex ratio of children and impact of parental diabetes in individuals with type 1 diabetes. Diabet Med 29(10):1268–1273. https://doi.org/10.1111/dme.2015-1137

43. Pozzilli P, Visalli N, Signore A et al (1991) Clinical remission in patients with IDDM and family history of NIDDM. Lancet 337(8750):1165. https://doi.org/10.1016/S0140-6736(91)91629-7

44. Redondo MJ, Muniz J, Rodriguez LM et al (2014) Association of TCF7L2 variation with single islet autoantibody expression in children with type 1 diabetes. BMJ Open Diabetes Res Care 2(1):e000008. https://doi.org/10.1136/bmjdrcc-2013-000008

45. Libman IM, Pietropaolo M, Arslanian SA, LaPorte RE, Becker DJ (2003) Changing prevalence of overweight children and adolescents at onset of insulin-treated diabetes. Diabetes Care 26(10):2871–2875. https://doi.org/10.2337/diabetes.26.10.2871

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.